With no proven evidence for further chemotherapy, we discussed the potential benefits of a combination regimen with DC/CIK infusions administered in conjunction with programmed death-1 (PD-1) and vascular endothelial growth factor (VEGF) inhibitors, based on encouraging outcomes with personalized cellular immunotherapy strategies in the minimal residual disease setting. The gene discussed is VEGFA; the disease is glycogen storage disease VI.